Tamoxifen Inhibitor CAS No. 54965-24-1

Cat. No.	Name	Size	Price	Add Cart
KI0468	Tamoxifen	250 mg	$154

Chemical Characteristic

Product Name	Tamoxifen
Synonyms	Nolvadex, Istubal, Valodex
CAS No.	54965-24-1
Molecular Weight	563.64
Formula	C₂₆H₂₉NO.C₆H₈O₇
Chemical Name	(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxyl]-N,N-dimethyl-ethanamine-citrate
Smiles	C(=O)(CC(O)(C(=O)O)CC(=O)O)O N(CCOc1ccc(cc1)/C(=C(/CC)\c1ccccc1)/c1ccccc1)(C)C
Chemical Structure
Documents	COA HPLC MS

Biological activities

Tamoxifen is a tissue-selective estrogen receptor modulator (SERM). In breast tissue tamoxifen, as a breast cancer therapeutic, is metabolized into hydroxytamoxifen which is an antiestrogen. In other tissues such as the endometrium, tamoxifen exerts its role as an agonist, and thus may be identified as a mixed agonist/antagonist. ^[1] Tamoxifen possesses antiproliferative activity. In an in vitro assay, tamoxifen inhibits protein kinase C competitively with respect to phospholipid. Tamoxifen produces effects on protein kinase C activity by depending on the phospholipid environment of the enzyme.^[2] Combing human IFN-α with tamoxifen or IFN-β with tamoxifen inhibits the growth of both MCF-7 and NIH-OVCAR-3 cells to a greater degree, compared with single agents. Tamoxifen regresses the mean tumor volume by 15%, compared with control tumor volume, in MCF-7 human breast carcinoma xenografts at the end of 10 weeks. However, combination of IFN-? and tamoxifen or IFNβ and tamoxifen prevents the tumor to an undetectable degree in mice.^[3] Tamoxifen suppresses the binding of [³H]nitrobenzylthioinosine ([³H]NBMPR) to human MCF-7 breast cancer cells with an IC50 of 8 μM. Tamoxifen at 30 μM increases the apparent Kd for [³H]NBMPR binding from 0.63 to 4.75 nM.^[4] Tamoxifen inhibits metastasis and prolongs overall survival. Intracellular levels of VEGF elevate in response to tamoxifen to levels similar to those observed post the treatment with estrogen. Tamoxifen downregulates extracellular VEGF levels in solid MCF-7 tumors. Plasma levels of VEGF in estradiol-treated animals are 10.5 pM compared with 12 pM in estradiol plus tamoxifen-treated mice. The vessel area is significantly decreased on tumor sections from animals treated with a combination of estradiol plus tamoxifen in comparison with estradiol treatment only (1.2% of total area versus 5%).^[5] In addition, tamoxifen prevents hepatocyte proliferation after partial hepatectomy. The injection of 1 μg tamoxifen per gm body weight at zero time or 6 hours after the operation leads to a marked suppression of not only DNA synthesis but also the number of cells in mitosis. Administrations of tamoxifen 12 hours or later after the surgery have no impact. Co-administrations of equimolar amounts of estrogen abolishes the prevention caused by tamoxifen.^[6] In another study, tamoxifen in combination with R115777 (tipifarnib) products synergistically inhibitory action on MCF-7 breast cancer cell in vitro and in vivo. The combination of tamoxifen and R115777 (a farnesyltransferase inhibitor) leads to significantly lower Ki-67 in comparison with either tamoxifen or R115777 alone (mean of 5% versus 16.9% and 67.3%, respectively).^[7]

Protocols

For in vitro experiments, 10 mg tamoxifen or estrogen were dissolved in 1 mL ethanol and were diluted in culture medium ( 0.4 to 1:1,000 v/v). ^[6]

References

[1] Liu XF, et al. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J Biol Chem. 2004, 279(15): 15050-15058. [2] Issandou M, et al. Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res. 1990, 50(18): 5845-5850. [3] Lindner DJ, et al. Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res. 1997, 17(11): 681-693. [4] Cai J, et al. Tamoxifen inhibits nitrobenzylthioinosine-sensitive equilibrative uridine transport in human MCF-7 breast cancer cells. Biochem J. 1996, 320 ( Pt 3): 991-995. [5] Garvin S, et al. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res. 2003, 63(24): 8742-8748. [6] Francavilla A, et al. The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology. 1989, 9(4): 614-620. [7] Martin LA, et al. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol Cancer Ther. 2007, 6(9): 2458-2467.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.

KareBay^TM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.

About

KareBay^TM Biochem
Sitemap
Blog

Custom Services